[Intravitreal ranibizumab for age-related macular degeneration].
Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period. A total of 647 eyes have so far been treated. In all 2,735 injections have been performed. Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0.001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild. Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.